
Oncology NEWS International
- Oncology NEWS International Vol 16 No 11
- Volume 16
- Issue 11
Ganz, Joranson receive ACS Distinguished Service Award
The American Cancer Society has given its Distinguished Service Award to Patricia Ganz, MD, director of cancer prevention and control research at UCLA's Jonsson Cancer Center, and to David E. Joranson, MSSW, Distinguished Scientist and recently retired director of the Pain and Policy Studies Group at the University of Wisconsin Carbone Comprehensive Cancer Center.
ATLANTAThe American Cancer Society has given its Distinguished Service Award to Patricia Ganz, MD, director of cancer prevention and control research at UCLA's Jonsson Cancer Center, and to David E. Joranson, MSSW, Distinguished Scientist and recently retired director of the Pain and Policy Studies Group at the University of Wisconsin Carbone Comprehensive Cancer Center.
Dr. Ganz, a professor in the UCLA Schools of Medicine and Public Health and a founding member of the National Coalition for Cancer Survivorship, was recognized for her major contributions and commitment in the field of cancer research. For 2 decades, Dr. Ganz has conducted ground-breaking research that has changed the face of cancer survivorship. Last year, she was selected to head up the UCLA-Livestrong Survivorship Center of Excellence, which addresses the needs of the ever-increasing number of cancer survivors in the United States.
Mr. Joranson was honored for his contributions to the study and modernization of narcotics control policies to remove barriers to pain patients' access to opioid analgesics, ACS said. As director of the World Health Organization Collaborating Center for Policy and Communications in Cancer Care, he has led efforts to achieve more balanced national drug control policies and improve patient access to pain drugs in developing countries.
Articles in this issue
about 18 years ago
MT103, BiTE antibody, enters phase II testing for ALLabout 18 years ago
Sides dig in as ESA policy debate heats upabout 18 years ago
Ixempra gets ok for resistant breast cancerabout 18 years ago
ASCO adds Oncotype DX to marker guidelineabout 18 years ago
Dr. Norton hopes to weed 'molecular' tumor gardenabout 18 years ago
Accelerated approval for Tasignaabout 18 years ago
Oxidative stress inducer ups survival in advanced melanomaabout 18 years ago
FDA removes partial hold on Telcyta clinical developmentabout 18 years ago
Should all HER2+ pts receive adjuvant trastuzumab?about 18 years ago
R-CHOP is standard of care for advanced DLBCL patientsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


















































































